Immune Biosolutions Receives C$13.44 Million to Develop and Biomanufacture its Promising Immunotherapy to Treat COVID-19 and its Variants

SHERBROOKE, QC, March 16, 2021 /CNW Telbec/ - Immune Biosolutions, an innovative biotechnology company, receives $13.44M from the Government of Canada's Strategic Innovation Fund (SIF) to develop its promising immunotherapy whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants. This funding will allow the immunotherapy currently in pre-clinical studies to progress to Phase II clinical trials. In addition, Immune Biosolutions will build a biomanufacturing capacity to accelerate the preclinical and clinical development of its therapeutic antibodies. About Immune Biosolutions Inc.
（以上内容由医药魔方AI生成）